EDG-5506: A Novel Small Molecule to Protect Dystrophic Muscle with Edgewise

October 13, 2021 2:00PM

Join us for a live webinar–EDG-5506: A Novel Small Molecule to Protect Dystrophic Muscle presented by Edgewise Therapeutics–as part of our Community Webinar Series. Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders.

“Our lead program, EDG-5506, is focused on Becker and Duchenne muscular dystrophies. We have successfully initiated Phase 1 healthy volunteer studies and plan to initiate studies in individuals with Becker in 2021. Our approach is novel and potentially complementary with current approaches, and works by directly targeting key muscle modulators.”

Guest Speakers

Joanne M. Donovan M.D., Ph.D.
Chief Medical Officer at Edgewise Therapeutics

Joanne M. Donovan, M.D., Ph.D., has been Chief Medical Officer at Edgewise Therapeutics, a biotechnology company focused on rare muscle disorders, since April, 2021. Dr. Donovan has been deeply involved in clinical development for Duchenne muscular dystrophy for the last decade in her role as Chief Medical Officer and Senior Vice President, Clinical Development at Catabasis Pharmaceuticals. Since 1989, she has been a staff physician at the VA Boston Healthcare System and is currently an Associate Clinical Professor of Medicine at Harvard Medical School. From 1998 to 2011, Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme. Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women’s Hospital.

Alan Russell, Ph.D.
Chief Scientific Officer and Co-Founder

Alan Russell, Ph.D., serves as our Co-Founder, Chief Scientific Officer and a member of our board of directors. Previously, Dr. Russell served at GlaxoSmithKline as VP and Head of the Muscle Metabolism Discovery Performance Unit, leading a broad discovery and development effort focused on patients for whom muscle function is compromised. Prior to this, he worked at Cytokinetics Inc. and is the co-inventor of Tirasemtiv and Reldesemtiv, direct muscle sensitizers in clinical trials for Amyotrophic Lateral Sclerosis (ALS). Dr. Russell received a B.Pharm. in Pharmacy and Pharmacology and Ph.D. in Cell Biology and Gene Therapy from the University of Bath in the UK and Postdoctoral training at the Stanford University School of Medicine.

Abby Bronson, MBA
VP Patient Advocacy and External Innovation

Abby Bronson has served as our Vice President of Patient Advocacy and External Innovation since April 2020. Ms. Bronson recently served as the Senior Vice President of Research Strategy at Parent Project Muscular Dystrophy (PPMD) where she managed the research portfolio and developed novel trial strategies to accelerate the clinical trial process in Duchenne. Prior to PPMD, she was the Director of Operations at the Division of Clinical Innovation at NCATS, NIH. She has also had senior positions at MedImmune and Children’s National Medical Center. She holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.A. from the University of Vermont.

Community Webinar Series - Better preparing for challenges in Duchenne

Jett Foundation invites all members of the Duchenne community to attend our Community Webinar Series! This series is focused on topics tailored to help individuals and families impacted by Duchenne learn more about care, clinical trials, resources, and support. We are committed to providing these 1-hour presentations to empower individuals and families with the tools and resources needed to be their own best advocates.

View Our Upcoming Educational Webinars

Please contact [email protected] with any questions or if you’d like to become a future speaker at one of our community webinars. We look forward to having you participate in these virtual community engagement events!

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open